Seres Therapeutics Inc (MCRB) Stock Price, Quote & News

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 9626

Website: www.serestherapeutics.com

Address:

101 Cambridgepark Drive, Cambridge, United States

BioCrazy1 Dec. 14 at 4:26 AM

$MCRB Why the borrow fee has fallen while the % of shares shorted hasnt changed: Increased lending supply from existing holders (e.g., institutions or insiders deciding to lend out more shares as squeeze risk perceptions declined). Reduced short demand intensity (shorts feeling more comfortable with the bearish outlook, perhaps due to delayed partnership news). Broader market dynamics or prime broker inventory changes. Share count is up an additional 300k shares from 8.75 million to 9.05 million. Overall, the share count bump could have played a supporting role by slightly expanding the pool, but the rapid fee decline points more to shifting perceptions of risk/scarcity among lenders and borrowers.

0 · Reply

MoneyGroupLLC Dec. 12 at 6:18 PM

Enter: $MCRB Calls Strike Price: $18 Expiry Date: JAN 16 2026 Buy in Price: $2.35 - $4.10 Sell Price: $4.56 Profit : +94% (Turn every $1 into $1.94) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

LionNoRichy Dec. 12 at 5:36 PM

$MCRB alright market is red again, we may expect a random pump xd (kidding)

0 · Reply

BioCrazy1 Dec. 12 at 5:17 AM

$MCRB Look at how that borrow fee just plunged. I love a good rigged market where the 1% know everything before it happens. I'd say news is close.

2 · Reply

BioCrazy1 Dec. 12 at 5:13 AM

$MCRB This meat stick finally changed his LinkedIn page! Those poor fcuks! LMFAO 😆😂🤣

1 · Reply

sem__sem Dec. 11 at 7:33 PM

$MCRB no one has seen LinkedIN post from Nestle CEO talking about micro biome pipeline…? We are still on their radar 😎

1 · Reply

BrilbeerBarry Dec. 11 at 4:27 PM

$MCRB

1 · Reply

SimpleWinningSetups Dec. 11 at 1:53 AM

📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $ARMP | Timeframe: 3M / 1H Market Cap: $206.43M • Pattern score: 0.73 • Current price: $5.890 • Peak (window): $11.760 • Trough (post-spike): $4.670 • Pullback: ~60.3% from peak • Move off lows: ~50.1% of peak Stock Plan (educational only) • Entry zone: $5.713 – $6.008 • Scalp target: $6.361 → Est. ROI: ~8.0% • Swing target: $9.408 → Est. ROI: ~59.7% • Protective stop: $5.006 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $MCRB

0 · Reply

MoneyGroupLLC Dec. 10 at 3:26 PM

Enter: $MCRB Calls Strike Price: $18 Expiry Date: JAN 16 2026 Buy in Price: $2.80 - $2.80 Sell Price: $5.96 Profit : +113% (Turn every $1 into $2.13) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

TotalChamp Dec. 10 at 3:04 PM

$MCRB still own all my shares here. But my inability to hit the sell button on the last pump is really dragging me down. Hardly check the board anymore. Hope to see news in early January that gets me an exit. Good luck all, especially those longs I’ve seen post in here from time to time. Been here since August 2024

4 · Reply

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 5, 2025, 2:11 PM EST - 5 weeks ago

Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 5 weeks ago

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 30, 2025, 7:00 AM EDT - 6 weeks ago

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

Oct 29, 2025, 7:00 AM EDT - 6 weeks ago

Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155

Oct 14, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Sep 23, 2025, 7:00 AM EDT - 2 months ago

Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway

Sep 22, 2025, 12:10 PM EDT - 2 months ago

More companies adopt co-CEO structure

IREN KKR LEN NFLX ORCL SBET

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 9:47 PM EDT - 4 months ago

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:23 PM EDT - 4 months ago

Seres (MCRB) Q2 Loss Narrows 34%

Aug 6, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Jul 29, 2025, 2:09 PM EDT - 4 months ago

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 22, 2025, 7:01 AM EDT - 5 months ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:00 AM EDT - 5 months ago

Seres Therapeutics Announces Leadership Transition

May 27, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 7, 2025, 2:18 PM EDT - 7 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 7 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 7:00 AM EDT - 8 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 23, 2025, 7:00 AM EDT - 8 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Mar 13, 2025, 11:04 AM EDT - 9 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 9 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 3, 2025, 7:00 AM EST - 10 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Jan 16, 2025, 7:00 AM EST - 11 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 1 year ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

BioCrazy1 Dec. 14 at 4:26 AM

0 · Reply

MoneyGroupLLC Dec. 12 at 6:18 PM

0 · Reply

LionNoRichy Dec. 12 at 5:36 PM

$MCRB alright market is red again, we may expect a random pump xd (kidding)

0 · Reply

BioCrazy1 Dec. 12 at 5:17 AM

$MCRB Look at how that borrow fee just plunged. I love a good rigged market where the 1% know everything before it happens. I'd say news is close.

2 · Reply

BioCrazy1 Dec. 12 at 5:13 AM

$MCRB This meat stick finally changed his LinkedIn page! Those poor fcuks! LMFAO 😆😂🤣

1 · Reply

sem__sem Dec. 11 at 7:33 PM

$MCRB no one has seen LinkedIN post from Nestle CEO talking about micro biome pipeline…? We are still on their radar 😎

1 · Reply

BrilbeerBarry Dec. 11 at 4:27 PM

$MCRB

1 · Reply

SimpleWinningSetups Dec. 11 at 1:53 AM

0 · Reply

MoneyGroupLLC Dec. 10 at 3:26 PM

0 · Reply

TotalChamp Dec. 10 at 3:04 PM

4 · Reply

Mikelonggggggggg Dec. 10 at 1:30 PM

$MCRB Shaff is now CEO at a bio startup called PsiThera lol. I feel sorry for that company.

1 · Reply

LionNoRichy Dec. 10 at 9:51 AM

$MCRB boys and ladies, we're getting less and less (old-timers) here, may we see a resolution to this mcrb case, for it's been too many years If you're a mcrib survivor, drop a hi xd

9 · Reply

BioCrazy1 Dec. 10 at 6:52 AM

$MCRB Shorts are fearless. I am not, sold at$24. The science and platform are spectacular but management is dog 💩. Wishing all remaining Iovaholics the best possible outcome!

1 · Reply

Tritsortreat2020 Dec. 9 at 10:35 PM

$MCRB i was really expecting short interest to be way down after 11/20 biggest trade day in over 2 years. virtually unchanged. no news, no filings. i guess it moved strictly due to options. Thoughts?

0 · Reply

SimpleWinningSetups Dec. 9 at 9:03 PM

Hedge Alert Live - Protect Your Portfolio Contract: $MCRB $15.00 Put · DEC 19, 2025 Exp Entry Price: $1.85 - $2.90 Exit Price Target: $3.50 Profit Margin: +89% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Thepark88 Dec. 9 at 7:52 PM

$MCRB short fee down to 18% now, like it’s slowly being walked down or a slow cover, not been this low for months

1 · Reply

jamstah Dec. 9 at 6:42 PM

$MCRB who bets on an announcement this week?

2 · Reply

MoneyGroupLLC Dec. 9 at 2:13 PM

Enter: $MCRB Calls Strike Price: $18 Expiry Date: JAN 16 2026 Buy in Price: $3.20 - $3.30 Sell Price: $5.54 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Tritsortreat2020 Dec. 9 at 1:59 PM

$MCRB best rule of thumb. dont ask anyone on stocktwits for a timeline on a buyout. THEY DONT KNOW 😂

1 · Reply

BIOhmygod Dec. 9 at 1:57 AM

$MCRB Is there absolutely no chance of a BO or partnership before Christmas? I recall there was talk about tax benefits involving Nestle before... If another year passes like this, we'll run out of cash next year, and then they'll have to raise capital again...

2 · Reply

TheFatherofLuke Dec. 8 at 6:29 PM

$MCRB wow last time i looked at this it was .75 cents what went on while i was in prison for insider trading?

3 · Reply

TotalChamp Dec. 8 at 2:11 PM

$MCRB we feeling any pre Christmas pops? I’m thinking not till after new years.

2 · Reply

Market Cap	153.25M
Revenue (ttm)	0.00
Net Income (ttm)	140,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	214.50
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	44,900
Avg Vol	189,924
Day's Range	N/A - N/A
Shares Out	9.05M
Stochastic %K	29%
Beta	0.18
Analysts	Sell
Price Target	$16.00